1-3 of 3
Weize Huang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Clinical Trials & Observations
Naval G. Daver, Monique Dail, Jacqueline S. Garcia, Brian A. Jonas, Karen W. L. Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph M. Brandwein, Arnaud Pigneux, Bayard L. Powell, Pierre Fenaux, Rebecca L. Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion G. Ott, Wan-Jen Hong, Marina Y. Konopleva, Michael Andreeff
Journal: Blood
Blood (2023) 141 (11): 1265–1276.
https://doi.org/10.1182/blood.2022016362
Published: 2023
Includes: Supplemental data
Journal Articles

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection

Mohamed A Badawi, Sheryl Coppola, Doerthe Eckert, Sathej Gopalakrishnan, Eva Doelger, Edyta Dobkowska, Shaji K Kumar, Weize Huang, Rajeev Menon, Ahmed Hamed Salem
Journal: Blood
Blood (2022) 140 (Supplement 1): 4281–4282.
https://doi.org/10.1182/blood-2022-166584
Published: 2022
Journal Articles

Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

Pankit Vachhani, Jonathan A. Abbas, Evelyn M. Flahavan, Esprit Ma, Tao Xu, Huan Jin, Melissa Montez, Weize Huang, Anda Gershon, Grace Ku, Brannon Flores, Maika Onishi, Cat N. Bui, William Donnellan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2290.
https://doi.org/10.1182/blood-2021-147851
Published: 2021